Navigation Links
3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
Date:9/25/2008

SHENYANG, China, Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration (SFDA) for approval of a 36,000 IU dosage formulation of EPIAO for the treatment of anemia associated with chemotherapy in cancer patients. If approved, high-dose EPIAO would be the only dosage form of this kind available in China.

High dose EPIAO is designed for the rapid restoration of hemoglobin to normal levels among cancer patients. The 36,000 IU dosage is comparable to the standardized dose used globally for the chemotherapy-induced anemia, allowing for less frequent administration than lower dosage forms, which in turn is expected to provide greater convenience for both patients and caregivers.

The clinical trial examined the safety and efficacy of a weekly subcutaneous injection of 36,000 IU EPIAO in oncology patients compared with a regimen of three times per week administration of 10,000 IU EPIAO. The results showed that 70% of the patients receiving high-dose EPIAO injections had Hemoglobin improvement of 1-2 g/dL from baseline, similar to those receiving three times per week dosing of 10,000 IU EPIAO. More importantly, the weekly administration of 36,000 IU EPIAO demonstrated equivalent safety and tolerability profiles as the three times per week 10,000 IU EPIAO.

Commenting on the news, Dr. Jing Lou, CEO of 3SBio, said, "I am pleased to announce that we have reached another important milestone for one of our key pipeline products. The submission for approval of high-dose EPIAO is based on positive
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... Stock Exchange Symbol: MS , ... , , ... ... EDMONTON , March 16 ... ...
(Date:3/16/2010)... PharmAthene, Inc. (Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results ... ... , ... ... ...
(Date:3/16/2010)... March 16 The Gynecologic Cancer Foundation (GCF) and the Claudia ... as the first recipient of the $50,000 GCF/Claudia Cohen Prize for Outstanding ... (SGO) 41st Annual Meeting on Women,s Cancer, meeting in San Francisco ... ... ...
(Date:3/16/2010)... (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice ... New Drug Application ("ANDA") for a generic version of Shire,s 1,mg, 2mg, ... ... ... , ...
Breaking Biology Technology:BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4
... Samter Journalism Awards ... Entry Deadline: October 31, 2007, MILWAUKEE, Sept. ... the largest professional medical specialty,organization in the United States representing ... special interest in the research and treatment of allergic disease,is ...
... 28 /PRNewswire-FirstCall/ - Neptune Technologies &,Bioressources Inc. (NASDAQ.NEPT ... for the fiscal year ended May 31, 2007. ... and operational,profitability while continuing its business development strategy ... in,sustainable sales growth. Financial Results and Highlights:, ...
... day, someone dies,of melanoma in the United States, making this ... worldwide. Since 1975, the incidence rate,of new melanomas has more ... and both sexes. Currently, there are more new,cases of melanoma ... early there is an excellent chance of recovery. Katie ...
Other Biology Technology:AAAAI: Call for Entries: Have You Written a Story on Allergic Disease? Win $1000 2Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results 2Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results 3Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers 2
(Date:3/18/2010)... can live for twenty years, fertilizing millions of eggs ... activity. , Danish researchers who have studied ants ... 1992 discovered that in both ant and bee species ... fluid favors the survival of its own sperm over ... stored, leafcutter ant queens neutralize male-male sperm competition with ...
(Date:3/18/2010)... available in Spanish . , Feeding ... as part of their regular diet makes them ... a study by Agricultural Research Service (ARS) scientists ... and overall behavioral activity among young female pigs ... acquired through diet, is the precursor for the ...
(Date:3/18/2010)... Biotech, Inc., ( www.genwaybio.com ) the US-based diagnostic company ... is expanding this cancer testing program internationally. An ... YouTM Cancer Assessment in Greece starting in April. ... as well. GenWay currently offers this test in ... Sergey Sikora, Vice President of Business Development, said, "The ...
Breaking Biology News(10 mins):Females shut down male-male sperm competition in leafcutter ants 2Tryptophan-enriched diet reduces pig aggression 2Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 1Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 2Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 1Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 1Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 3
... mouse repeatedly experiences defeat by a dominant animal disappears ... in a brain circuit for social learning, scientists funded ... of Mental Health (NIMH) have discovered. Mice engineered ... in spite of repeated social defeat. Their unaltered peers ...
... M. Erickson sliced up some ancient dinosaur bones ... of scientists identify a new genus and species. ... the FSU researcher determined that the two remarkably ... Tyrannosaurus rex. , Make that distant cousins –?the ...
... Services (HHS) today announced the creation of two new, ... causes of common diseases such as asthma, arthritis and ... the National Institutes of Health (NIH) for a multi-institute ... common illnesses. The other initiative launches a public-private partnership ...
Other Biology News:Mice lacking social memory molecule take bullying in stride 2Mice lacking social memory molecule take bullying in stride 3FSU biologist says new dinosaur is oldest cousin of Tyrannosaurus rex 2FSU biologist says new dinosaur is oldest cousin of Tyrannosaurus rex 3Two NIH initiatives launch intensive efforts to find roots of common diseases 2Two NIH initiatives launch intensive efforts to find roots of common diseases 3Two NIH initiatives launch intensive efforts to find roots of common diseases 4Two NIH initiatives launch intensive efforts to find roots of common diseases 5Two NIH initiatives launch intensive efforts to find roots of common diseases 6Two NIH initiatives launch intensive efforts to find roots of common diseases 7Two NIH initiatives launch intensive efforts to find roots of common diseases 8
...
... agent. Inhibits several important steps of angiogenesis including ... cells. Also reduces intracellular reactive oxygen species (ROS) ... endothelial cells. Formula: ... MolWeight: 360.31484 ...
... Zero Background Cloning Kit includes the pZErO-1 ... E. coli. The pZErO-1 vector utilizes positive ... size of the Zeocin resistance gene reduces ... and transformation efficiencies. The kit contains all ...
NATIVE, ENZYME PORCINE TRYPSIN...
Biology Products: